-+ 0.00%
-+ 0.00%
-+ 0.00%
BioPorto 9M adjusted EBITDA loss narrows 19% to DKK 51.5 million
Share
Listen to the news
BioPorto 9M adjusted EBITDA loss narrows 19% to DKK 51.5 million
  • BioPorto reported a third-quarter 2026 adjusted EBITDA loss of DKK 16.8 million.
  • The U.S. adult validation study entered active execution, with study sites activated and the first patients enrolled during the quarter.
  • Five U.S. university hospitals became NGAL research-use customers, bringing the total to 59 at quarter-end.
  • Full-year 2026 guidance remained unchanged, including an adjusted EBITDA loss of DKK 58 million–DKK 68 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioPorto A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190153OMX_____CNEWS_DA_GNW1001304423_da) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending